Examkin

Question

Difficulty: HardPharmacokinetic and Pharmacodynamic Principles

A retired teacher with longstanding nonvalvular atrial fibrillation is brought to the emergency department by ambulance following an episode of syncope and large volume melena. He is 74 years old and has been successfully managed on a stable dose of dabigatran for the past three years. His past medical history is also significant for hypertension, for which he takes lisinopril and metoprolol. Two weeks prior to presentation, he was diagnosed with widespread onychomycosis by a dermatologist and was prescribed a three-month course of oral itraconazole. Upon arrival, his blood pressure is 88/54 mmHg88/54\text{ mmHg}, and his heart rate is 115/min115\text{/min}. Initial laboratory evaluation reveals a hemoglobin concentration of 6.8 g/dL6.8\text{ g/dL} and a significantly prolonged activated partial thromboplastin time. Which of the following pharmacokinetic or pharmacodynamic mechanisms most accurately explains the adverse event observed in this patient?

  1. Increased oral bioavailability due to inhibition of an intestinal efflux transporterAnswer
  2. B
    Decreased hepatic biotransformation due to inhibition of a microsomal enzyme
  3. C
    Decreased renal elimination due to competition for active tubular secretion
  4. D
    Increased fraction of unbound active drug due to displacement from plasma proteins
  5. E
    Decreased synthesis of vitamin K-dependent coagulation factors due to altered intestinal microbiome

Answer

The correct answer is the mechanism describing increased oral bioavailability due to inhibition of an intestinal efflux transporter.
The correct answer accurately describes the mechanism of toxicity. Dabigatran etexilate is an oral prodrug that acts as a direct thrombin inhibitor. It is a major substrate of P-glycoprotein (P-gp), an efflux transporter located on the apical membrane of intestinal enterocytes that pumps xenobiotics back into the gut lumen, effectively limiting their bioavailability. Itraconazole is a potent inhibitor of P-gp. Co-administration blocks this protective efflux mechanism, leading to a profound increase in the absorption and oral bioavailability of dabigatran. This results in supratherapeutic plasma concentrations and a correspondingly high risk of life-threatening hemorrhage. Unlike other DOACs (e.g., rivaroxaban, apixaban), dabigatran is not metabolized by the cytochrome P450 system, making the P-gp interaction the definitive cause of this adverse event.

Step-by-Step Solution

1
Identify the primary clinical presentation.
The patient presents with hemorrhagic shock (hypotension, tachycardia, melena, severe anemia) and a prolonged aPTT while taking dabigatran, indicating acute anticoagulant toxicity.
Establishing the nature of the clinical emergency focuses the analysis on identifying the precipitating cause of the toxicity.
2
Analyze the medication regimen for newly introduced drugs.
The patient recently started itraconazole, an azole antifungal, two weeks prior to the onset of bleeding.
Recent additions to stable medication regimens are the most common precipitants of acute pharmacokinetic drug-drug interactions.
3
Evaluate the pharmacokinetic profile of both the affected drug and the precipitant.
Dabigatran etexilate is a prodrug that is a substrate for the P-glycoprotein (P-gp) efflux pump in the intestine, but it is not metabolized by CYP450 enzymes. Itraconazole is a strong dual inhibitor of both P-gp and CYP3A4.
Understanding the specific metabolic and transport pathways is required to distinguish the mechanism from interactions affecting other similar drugs.
4
Determine the precise mechanism of the interaction.
By inhibiting intestinal P-gp, itraconazole prevents the normal efflux of unabsorbed dabigatran etexilate back into the gastrointestinal lumen. This vastly increases the amount of drug absorbed into the systemic circulation, causing supratherapeutic levels and subsequent hemorrhage.
This establishes the causal link between the two medications and the patient's presentation.

Key Concept

Drug-drug interactions involving P-glycoprotein (P-gp) efflux transporters, specifically the increased bioavailability of dabigatran when co-administered with a potent P-gp inhibitor like itraconazole.
Rate this question

Topics

Pharmacokinetic and Pharmacodynamic Principles

More questions from this topic